bioAffinity Technologies Selected as Finalist for Cancer Innovation Award
March 06, 2019 11:00 ET
|
bioAffinity Technologies, Inc.
SAN ANTONIO, March 06, 2019 (GLOBE NEWSWIRE) -- Healthcare innovators Lyfebulb and Helsinn selected bioAffinity Technologies, a privately held biotech company developing diagnostics and therapeutics...
Helsinn Investment Fund: Ten finalists have been chosen for the second annual Lyfebulb-Helsinn Innovation Summit & Awards in Oncology
February 27, 2019 08:15 ET
|
Helsinn Healthcare S.A.
Ten finalists have been chosen for the second annual Lyfebulb-Helsinn Innovation Summit & Awards in Oncology The Award recognizes Patient Entrepreneurs’ innovations for cancer and cancer...
Helsinn Investment Fund Invests €1 Million in Gain Therapeutics
February 19, 2019 02:30 ET
|
Helsinn Healthcare S.A.
Helsinn Investment Fund Invests €1 Million in Gain Therapeutics Luxembourg, February 19, 2019: Helsinn Investment Fund S.A, SICAR, a fund focused on early-stage investment opportunities in areas of...
Helsinn and MEI Pharma Announce Publication of Phase II Data for Pracinostat in Combination with Azacitidine in Blood Advances
February 14, 2019 15:22 ET
|
Helsinn Healthcare S.A.
Helsinn and MEI Pharma Announce Publication of Phase II Data for Pracinostat in Combination with Azacitidine in the Frontline Treatment of Older AML Patients Unfit for Intensive Chemotherapy, in Blood...
Helsinn Provides Educational Grant for ESMO’s Preceptorship for Supportive and Palliative Care
January 31, 2019 03:00 ET
|
Helsinn Healthcare S.A.
Helsinn Provides Educational Grant for ESMO’s Preceptorship for Supportive and Palliative Care Lugano, Switzerland, January 31, 2019 – Helsinn, a Swiss pharmaceutical group focused on...
Helsinn Group Announces new Permanent J Code for AKYNZEO® (fosnetupitant and palonosetron) for injection in the US
January 02, 2019 08:00 ET
|
Helsinn Healthcare S.A.
Helsinn Group Announces new Permanent J Code for AKYNZEO® (fosnetupitant and palonosetron) for injection in the US Akynzeo® for injection received a permanent J code, J1454, in the US, by the...
RECORDATI AND HELSINN AGREEMENT FOR THE EXCLUSIVE COMMERCIALIZATION RIGHTS TO LEDAGA®
December 20, 2018 07:00 ET
|
Helsinn Healthcare S.A.
RECORDATI AND HELSINN AGREEMENT FOR THE EXCLUSIVE COMMERCIALIZATION RIGHTS TO LEDAGA® Milan and Lugano, December 20, 2018 – Recordati and Helsinn announce the signing of a license agreement between...
Phase 2 Interim Data Evaluating the Combination of Pracinostat and Azacitidine in Patients with Myelodysplastic Syndrome Presented at the 2018 American Society of Hematology Annual Meeting
December 03, 2018 12:30 ET
|
Helsinn Healthcare S.A.
Phase 2 Interim Data Evaluating the Combination of Pracinostat and Azacitidine in Patients with Myelodysplastic Syndrome Presented at the 2018 American Society of Hematology Annual Meeting LUGANO,...
Helsinn Group supports Satellite Symposium at 14th EADO Congress 2018
November 06, 2018 03:00 ET
|
Helsinn Healthcare S.A.
Helsinn Group supports Satellite Symposium at 14th EADO Congress 2018 Lugano, Switzerland, November 6, 2018 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products,...
Helsinn Group strengthens the Board with the appointment of Francesco Granata
October 01, 2018 05:05 ET
|
Helsinn Healthcare S.A.
Helsinn Group strengthens the Board with the appointment of Francesco Granata LUGANO, October 1, 2018: Helsinn Group, a Swiss pharmaceutical group focused on building quality cancer care products,...